SCHEMBL2744136

SCHEMBL2744136

CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)OCc1nc2c(N)nc3ccccc3c2n1CCCCNS(C)(=O)=O

nearest known ligand 0.62

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 19/20 0.62
HDAC1 Q13547 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
TLR8 Q9NR97 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2744083 0.86 TLR7 (0.70) TLR7TLR8
SCHEMBL2744632 0.79 TLR7 (0.81) TLR7TLR8
Cpg-52852 SCHEMBL483385 0.78 TLR7 (1.00) TLR7TLR8
SCHEMBL14516458 0.78 TLR7 (0.75) TLR7TLR8
SCHEMBL3968461 0.77 TLR7 (0.76) TLR7TLR8
SCHEMBL483689 0.76 TLR7 (0.85) TLR7TLR8
SCHEMBL728965 0.76 TLR7 (0.78) TLR7TLR8
SCHEMBL14592877 0.76 TLR7 (0.61) TLR7TLR8
SCHEMBL728467 0.76 TLR7 (0.84) TLR7TLR8
SCHEMBL1490819 0.76 TLR7 (0.68) TLR7TLR8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-8178677-B2 Hydroxyalkyl substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-05-15 US disclosed
US-8178677-B2 Hydroxyalkyl substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-05-15 US disclosed
US-8178677-B2 Hydroxyalkyl substituted imidazoquinolines 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-05-15 US disclosed
US-20090029988-A1 Hydroxyalkyl Substituted Imidazoquinolines COLEY PHARMACEUTICAL GROP, INC. (US) 2009-01-29 US disclosed
US-20090029988-A1 Hydroxyalkyl Substituted Imidazoquinolines COLEY PHARMACEUTICAL GROP, INC. (US) 2009-01-29 US disclosed
US-20090029988-A1 Hydroxyalkyl Substituted Imidazoquinolines COLEY PHARMACEUTICAL GROP, INC. (US) 2009-01-29 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon IFNG, IFNAR1, EIF2AK2 TLR7 194/4885HDAC1 2292/4885HDAC6 1429/4885
US-20090029988-A1 Hydroxyalkyl Substituted Imidazoquinolines IFNG, IRF3, IFNAR1 TLR7 55/4885HDAC1 1430/4885HDAC6 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.